Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  vorinostat
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 134 for your search:
Start Over
Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 3 to 21
Sponsor: NCI
Protocol IDs: NCI-2011-02616, CDR0000688443, ACNS0822, U10CA098543, COG-ACNS0822, NCT01236560
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
Phase: Phase III, Phase II
Type: Tissue collection/Repository, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-00242, SWOG-S1117, CDR0000723909, S1117, U10CA180888, U10CA032102, NCT01522976
Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (0683-014 AM5, EXT1)
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 0683-014, 2005_010, CTRI/2009/091/000146, NCT00128102
Phase III Randomized Study of Vorinostat (SAHA) in Patients With Progressive or Relapsed Advanced Malignant Pleural Mesothelioma
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: NCI-06-C-0040, MERCK-014-01, NCI-P6690, NCT00265577, UCLA-0506053-01, MERCK-014-00
Study of Vorinostat (MK-0683) an HDAC Inhibitor, or Placebo in Combination With Bortezomib in Patients With Multiple Myeloma (MK-0683-088 AMN)
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 0683-088, 2008_525, NCT00773747
Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00093, NA 00001107, NCI-6884, JHOC-J0570, CDR0000467800, 6884, JHOC-00001107, J0570, IRB #NA 00001107, SKCCC J0570, U01CA070095, U01CA062491, NCT00324870
Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 21 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00095, NYWCCC-0511008257, CDR0000472916, NCI-6896, 0511008257, 6896, N01CM62204, P30CA013330, NCT00324740
Vorinostat, Paclitaxel, and Bevacizumab in Treating Patients With Metastatic Breast Cancer and/or Breast Cancer That Has Recurred in the Chest Wall and Cannot be Removed by Surgery
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-03012, 06-05-291, 7703, N01CM62204, N01CM62207, N01CM62205, N01CM62209, AECM-0605291, NCI-7703, NCT00368875
Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-01050, CDR0000511887, NYCC-6898, NCI-6898, 11-1773, 6898, N01CM17103, N01CM62204, P30CA013330, NCT00392353
Clinical Trial of SAHA in Patients With Breast Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: BR05/24/06, DSRB Reference Code: B/06/275, HSA No: CTC0600314, NCT00416130
Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM)
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 2006-0709, NCI-2010-00782, 4808704, NCT00555399
Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: PSOC 2302, NCI-2010-00870, 6632, FHCRC-IR-6632, NCT00601718
Trial of Vorinostat in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 60 and over
Sponsor: Other
Protocol IDs: 08-045, NCT00667615
Carboplatin and Etoposide in Combination With Vorinostat for Patients With Extensive Stage Small Cell Lung Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: PSHCI 08-005, NCT00702962
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00672, CDR0000609743, ABTC 0902, N0874, U10CA180821, U10CA025224, NCCTG-N0874, NCT00731731
Vorinostat and Low Dose Cytarabine for High Risk Myelodysplasia
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: GFM VOR 2007-01, NCT00776503
SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 2008-0484, NCT00787527
Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: UMCC 2008.095, NCT00810602
Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 50 and over
Sponsor: NCI
Protocol IDs: NCI-2012-01147, IR-6921, CDR0000642213, 2288.00, 8297, P30CA015704, FHCRC-2288.00, NCT00895934
Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: PSOC 2401, NCI-2010-00324, P30CA015704, IR-6956, MERCK-PSOC-2401, NCT00918723
Suberoylanilide Hydroxamic Acid (SAHA), Bevacizumab, Daily Temozolomide for Recurrent Malignant Gliomas
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: Pro00016446, NCT00939991
Vorinostat in Combination With Radiation Therapy and Infusional Fluorouracil (5-FU) in Patients With Locally Advanced Adenocarcinoma of the Pancreas
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 09-114, NCT00948688
Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-01964, CDR0000653803, S0806, U10CA032102, SWOG-S0806, NCT00972478
Study of Vorinostat and Gefitinib in Relapsed/ or Refractory Patients With Advanced Non-small Cell Carcinoma (NSCLC)
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: NCCCTS-09-433, NCT01027676
Study of Vorinostat Plus Capecitabine (X) and Cisplatin (P) for 1st Line Treatment of Metastatic or Recurrent Gastric Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 to 70
Sponsor: Other
Protocol IDs: AMC-ONCGI-0903, NCT01045538
Start Over